Vyriad signs 'huge' deal with Novartis to develop new cancer treatments [Yahoo! Finance]
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3 [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.